CD4 and cancer: In general, there was a trend for higher frequencies to be observed in HC compared with patients with cancer (Fig. 2B) at 6 months following the second dose of the vaccine, although this only reached statistical significance when the frequency of AIM+CD8+ cells and the absolute numbers of AIM+CD4+ T cells were compared across HCs and patients with HM.